CIK 0002022626
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Upstream Bio, Inc.
Sign in to watch- Ticker
- UPB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 781-208-2466
- Business address
- 890 WINTER STREET, SUITE 200, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $27,604
- in 5 filings
Net −$27,604. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-16 | Deykin Aaron Chief Medical Officer | Sale | −895 | $5.49 | $5K | 32,302 |
| 2026-06-16 | Deykin Aaron Chief Medical Officer | Sale | −895 | $6.10 | $5K | 33,197 |
| 2026-03-16 | Deykin Aaron Chief Medical Officer | Sale | −894 | $9.29 | $8K | 32,687 |
| 2026-01-02 | Deykin Aaron Chief Medical Officer | Grant or award | +32,000 | 33,581 | ||
| 2026-01-02 | Deykin Aaron Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +96,000 | 96,000 | ||
| 2025-02-06 | Deykin Aaron Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +165,000 | 165,000 |
Page 1 of 1 · 6 trades